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Background:  Risk  assessments  are  widely  used,  but  their  ability  to  predict  outcomes  in opioid  use  disorder
(OUD) treatment  remains  unclear.  Therefore,  the  aim  was  to investigate  if addiction-speciﬁc  brief  risk
screening  is  effective  in  identifying  high  mortality  risk  groups  and if subsequent  clinical  actions  following
risk  assessment  impacts  on  mortality  levels.
Methods:  Opioid  use  disorder  (OUD)  patients  were  identiﬁed  in the South  London  and  Maudsley  Case
Register.  Deaths  were  identiﬁed  through  database  linkage  to the national  mortality  dataset.  Cox  and
competing-risk  regression  were  used  to model  associations  between  brief  risk  assessment  domains  and
all-cause  and  overdose  mortality  in  4488  OUD patients,  with  up-to 6-year  follow-up  time  where  227
deaths  were  registered.  Data  were  stratiﬁed  by admission  to  general  mental  health  services.
Results:  All-cause  mortality  was  signiﬁcantly  associated  with  unsafe  injecting  (HR  1.53,  95%  CI 1.10–2.11)
and  clinically  appraised  likelihood  of  accidental  overdose  (HR 1.48,  95%  CI  1.00–2.19).  Overdose-mortality
was  signiﬁcantly  associated  with  unsafe  injecting  (SHR  2.52,  95%  CI 1.11–5.70)  and  clinically  appraised
suicidality  (SHR  2.89,  95% CI  1.38–6.03).  Suicidality  was  associated  with  a  twofold  increase  in mortality
risk  among  OUD  patients  who  were  not  admitted  to mental  health  services  within  2 months  of  their  risk
assessment  (HR  2.03,  95% CI  1.67–3.24).
Conclusions:  Diagnosis-speciﬁc  brief  risk screening  can  identify  OUD patient  subgroups  at  increased  risk
of all-cause  and  overdose  mortality.  OUD  patients,  where  suicidality  is  evident,  who  are  not  admitted
into  services  are  particularly  vulnerable.
© 2016  The  Author(s).  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
People dependent on heroin or other opioids are up to 14
times more likely to die than their peers (Darke and Ross, 2002).
Worldwide, an estimated 69,000 people die from opioid overdose
(accidental or deliberate) each year (World Health Organisation
(WHO), 2014). In England and Wales, more than 1700 deaths reg-
istered in 2014 (53% of all deaths from drug poisoning) involved an
opiate drug (Ofﬁce For National Statistics (ONS), 2015). Assessing
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of  Psychiatry Psychology and Neuroscience, King’s College London, SE5 8AF London,
UK.
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and managing risks is a paramount element of care planning and
treatment provision to people with drug dependence, particularly
in opioid dependence (Department of Health (DOH), 2007). Assess-
ment of risks within the addictions services should be substance
misuse speciﬁc, prioritizing directly related risks such as overdose,
poly-drug use, suicide and/or unsafe injecting practices (National
Treatment Agency for Substance Misuse (NTA), 2006a,b).
The effectiveness of risk assessment tools in predicting mortal-
ity in mental healthcare is unclear. Wand, 2012 reported inability
to conduct a systematic review due to paucity of studies evaluat-
ing the effectiveness of risk assessments, and found little evidence
to conclude whether risk assessments are effective in relation
to self-harm or suicide reduction. Studies attempting to identify
individuals who are likely to die by suicide have been largely unsuc-
cessful primarily due to its low prevalence, even within high-risk
http://dx.doi.org/10.1016/j.drugalcdep.2016.04.036
0376-8716/© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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groups (Harriss and Hawton, 2005; Kapur, 2005). A recent study of
people receiving secondary mental healthcare reported that the
level of clinically appraised risk of self-neglect (but not suicide
or violence) predicted all-cause mortality, but the study did not
stratify results by diagnosis or examined cause-speciﬁc mortality
(Wu  et al., 2012). Given the differences in aetiology, symptoms,
care provision and risk factors between mental health diagnostic
groups, it is important to investigate these separately as advised
by the NTA (2006a). Therefore, the aim of the current study was
to determine if addiction-speciﬁc brief risk assessment completed
for opioid use disorder patients is effective in predicting risks of
all-cause and overdose mortality; to investigate mortality levels
in patients clinically appraised as displaying suicidality, increased
likelihood of accidental overdose and unsafe injecting practices;
and to determine if associations between clinically appraised risks
and mortality differs depending on subsequent clinical actions such
as admission to secondary mental health services and the type of
opioid substitution therapy (OST) prescribed.
2. Methods
2.1. Study setting
South London and Maudsley NHS Foundation Trust (SLaM) is
one of the largest secondary mental healthcare services in Europe,
currently providing comprehensive mental healthcare and addic-
tion service to a catchment population of approximately 1.2 million
residents across seven ethnically and socially diverse, high popu-
lation density boroughs of south London. SLaM addiction services
have used electronic health records (EHRs) since April 2008. In the
same year, at the SLaM NIHR Biomedical Research Centre for Mental
Health, the Clinical Record Interactive Search (CRIS) was  devel-
oped. CRIS uses EHRs in a de-identiﬁed format, allowing researchers
to search and retrieve complete case records for analytical pur-
poses. There are currently more than 260,000 patients represented
on the system. CRIS was approved as a dataset for secondary
analysis by Oxfordshire Research Ethics Committee C (reference
08/H0606/71+5), and its protocol is described in detail elsewhere
(Perera et al., 2016; Stewart et al., 2009).
2.2. Inclusion criteria
Diagnoses in SLaM are coded in accordance with the 10th edi-
tion of the World Health Organization International Classiﬁcation of
Diseases (ICD-10; WHO, 1993). This study cohort comprised SLaM
patients who were diagnosed with an ICD-10 F11 primary or sec-
ondary opioid use disorder (OUD) between 1st April, 2008 to 31st
March, 2014 (inclusive), and who had at least one item completed
on the Brief Risk Scale Assessment—Addiction (BRSA-A) during the
observation period. Diagnoses were derived from their designated
SLAM EHR structured ﬁelds and from free-text ﬁelds using Natu-
ral Language Processing (NLP). The NLP application for ‘diagnosis’
sought to extract any text strings associated with a diagnosis state-
ment in order to supplement the existing structured ﬁelds. The
performance of the ‘diagnosis’ NLP application was evaluated for-
mally elsewhere (Sultana et al., 2014). In the SLaM case register,
OUD is the second most frequently diagnosed substance use disor-
der after alcohol use dependence (Hayes et al., 2011).
2.3. Main outcome measures
2.3.1. All-cause mortality. The main outcome in this study was all-
cause mortality in individuals with primary or secondary diagnosis
of OUD, within the period 1st April, 2008 to 31st March, 2014. Every
death in the UK is reported to the Ofﬁce for National Statistics
General Records Ofﬁce, which is then conveyed to the NHS Care
Records Service and available to all NHS organisations. Majority of
deaths are registered with ONS within ﬁve days and SLaM mortal-
ity updates are performed on a monthly basis. This allowed us to
establish deaths within the observation period, for both active and
inactive SLaM patients. The full procedure for identifying and con-
ﬁrming SLaM patient deaths has been described elsewhere (Chang
et al., 2010).
2.3.2. Cause-speciﬁc mortality. Additionally, 68.7% of all those who
died had death certiﬁcate information. This information allowed us
to establish cause-speciﬁc mortality, and more speciﬁcally coding
for overdose mortality. Fatal overdoses included a combination of
both intentional (i.e., suicide) and unintentional (i.e., drug poison-
ing) overdose deaths, with ICD-10 codes X409-X450, Y120, Y125
and F119 sub-classiﬁed as such. The relationship between heroin
overdose and suicide is problematic due to ambiguous circumstan-
tial information and unclear intent (Cantor et al., 2001), therefore
for these analyses, we grouped suicide by overdose and fatal drug
poisonings into one group. The cause of death information is based
on a static ONS-CRIS data linkage and is more likely to reﬂect a pro-
portion of delayed as well as recent occurrences of deaths within
the ONS (ONS, 2011), resulting in the 31% missing causes of death
in our cohort.
2.4. Exposures
The main exposures of interest in this study were patients’ risks
of suicidality, likelihood of overdose and injecting practices. These
three risk domains were recorded using the Addiction Brief Risk
Scale Assessment (BRSA-A) (described below) in patients with OUD
In addition to the main exposures of interest, a number of other
covariates were considered as potential confounders. Patients’
risks associated with violence, health, social variables, and ser-
vice use were also recorded on the BRSA-A. Ethnicity and gender
are routinely recorded on SLaM electronic patient records in their
designated ﬁelds. Age was calculated on the date on which individ-
uals received their ﬁrst BRSA-A assessment within the observation
period. Ethnic group classiﬁcations were condensed to “White
British”, “Other White background”, “African, Caribbean and other
black background”, and “Mixed, unknown and other”. Area-level
deprivation was established by linking the patient’s residential
postcode to the UK Census data projected for 2007 in lower
super output area units. The full procedure for measuring level
of deprivation is described elsewhere (Hayes et al., 2012). Home-
lessness variable was  established by merging information from
area-level deprivation and homelessness/unstable housing item on
the BRSA-A scale. Information on patient admissions to a SLaM
secondary mental health service in the two-month period after
BRSA-A assessment was  also extracted. This information included
general admissions to SLaM, and information on prescription
of opioid substitute treatment (OST) medication (i.e., buprenor-
phine, methadone, Suboxone [buprenorphine/naloxone]) in the
2-month period after BRSA-A completion. Information extracted
included both inpatient and outpatient community service admis-
sions/prescriptions in a 60-day (two months) observation period
after the BRSA-A completion.
2.5. Risk assessment instrument
The BRSA-A is a compulsory target for the addictions clinical
team on all active cases. This risk measure was developed by SLaM
clinicians to encourage identiﬁcation and formal recording of risk
areas speciﬁc to substance misuse patients; these are then used
in their care planning. BRSA-A should be completed for each ser-
vice user at the point of referral, as part of the service user’s initial
assessment when he/she ﬁrst comes into contact with SLaM ser-
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Table  1
Cohort characteristics.
Variables Number of
individuals
Number of deaths
(% per row)
Total 4488 227 (5.1)
BRSA-A items and domains
Suicide
Suicide attempt history 1279 91 (7.1)
Suicide ideations 306 13 (4.2)
Carer concern 205 17 (8.3)
Major mental illness 1225 75 (6.1)
Accidental Overdose
Reduced tolerance 738 47 (6.4)
Recent abstinence 823 41 (5)
Alcohol abuse 1220 109 (8.9)
Poly-substance 2615 155 (5.9)
Injecting
Previously injecting 1433 102 (7.1)
Currently injecting 1047 81 (7.7)
High risk injector 515 49 (9.5)
Share injecting equipment 367 32 (8.7)
Violence
Violent past 1051 45 (4.3)
Violent thoughts 84 5 (6)
Violent Behaviour 119 8 (6.7)
Violence Concern 117 10 (8.6)
Health BRSA Items
BBV Infections 900 92 (10.2)
Hist of s.rel.sezures 588 59 (10)
Unmet needs 717 92 (12.8)
Cognitive impairment 220 24 (10.9)
High risk sexual behaviour 258 14 (5.4)
Social BRSA Items
Homeless/unstable housing 1341 76 (5.7)
Childcare/social service problems 392 17 (4.3)
social isolation 1246 88 (7.1)
self-neglect 816 74 (9.1)
criminal activity 1037 47 (4.5)
Service Use Items
Erratic engagement 880 56 (6.4)
Socio-demographic variables
Age at assessment
15–24 358 9 (2.1)
25–29 614 13 (2.1)
30–34 833 36 (4.3)
35–39 888 47 (5.3)
40–44 869 45 (5.2)
45–49 536 33 (6.2)
50+ 390 44 (11.3)
Gender
Males 3224 166 (5.2)
Females 1264 61 (4.8)
Ethnicity
White British 3002 170 (5.7)
Other White 622 32 (5.1)
Black 466 15 (3.2)
Mixed, unknown & other 398 10 (2.5)
Level of deprivation (in tertiles)
Low (2.19–27.42) 1468 67 (4.6)
Moderate (27.43–37.0) 1470 77 (5.2)
High (37.1+) 1474 82 (5.6)
vices. The completion of the BRSA-A assists in informing clinical
staff whether a full risk screen is then required (SLaM, 2011).
The BRSA-A includes twenty-seven binary items (0 = no risk;
1 = risk detected). These individual items have been sub-classiﬁed
into seven risk domains: suicidality, accidental overdose, inject-
ing practices, violence, health, social, and service use. The full
list of individual BRSA-A items and their classiﬁed risk domains
are presented in Table 1. For analytical purposes we  collapsed
relevant BRSA-A items into three domains as exposures of
interest—suicidality, likelihood of accidental overdose and unsafe
injecting practice. The suicidality domain consisted of suicide
attempt history, suicidal ideation, carer concern and major mental
illness items. The likelihood of accidental overdose domain con-
sisted of reduced tolerance, recent abstinence, alcohol abuse and
poly-substance use. The unsafe injecting domain included previ-
ous/current injecting, high risk injecting, and sharing of injecting
equipment items. A score of 1 was  assigned if any item within a
given risk domain was scored as present; or 0 if all items within that
risk domain were scored as absent—this increased power for all-
cause and cause-speciﬁc overdose investigations. We  chose to focus
on these three domains as exposures because of their likely impact
relationship on mortality in this patient group (World Health
Organisation, 2013). Remaining BRSA-A items were included in
analyses individually, as potential confounders.
2.6. Statistical analysis
Having checked proportional hazards assumptions, Cox regres-
sion (Cox, 1972) survival analyses were used to model the
associations between the suicidality, accidental overdose, unsafe
injecting domains (obtained from the ﬁrst BRSA-A assessment in
the observation period) and all-cause mortality. Competing risk
regression was  performed to model cause-speciﬁc overdose deaths
for the same domains. Patients’ ‘at risk’ periods commenced from
the date of their ﬁrst BRSA-A assessment within the observation
period (between 1 April, 2008 to 31 March, 2014) and ended on
the day of their death or the end of observation period, whichever
came ﬁrst. We  used likelihood ratio tests to examine potential
interactions between risk domains and admissions to SLaM ser-
vices in the two-month period after the assessment was  conducted,
and between risk domains and the OST prescriptions in the same
observation period. Where a signiﬁcant interaction was  found we
stratiﬁed the data accordingly and re-ran the Cox models with all-
cause mortality as the outcome. Kaplan–Meier survival curves were
used to visualize results for stratiﬁed analyses. All analyses were
conducted using STATA 12, with signiﬁcance levels at p < 0.05.
3. Results
The total number of patients with primary or secondary ICD10
F11 OUD diagnosis within the six-year period between 1st April,
2008 and 31st March, 2014 was 5335 and BRSA-A was completed
for 84.1% (n = 4488) of those. There were no signiﬁcant differences
between age (calculated at midpoint observation period for this
comparison), gender, ethnicity and mortality in people with and
without completed BRSA-A assessments. There were no individual
missing items within the group who  had the BRSA-A completed.
Therefore, the total number of individuals who  met the inclusion
criteria and whose data were extracted for analysis were 4488
(71.8% male; 66.9% “White British”), with 227 registered deaths
(detailed in Table 1). Patients contributed a total of 17,804.59 at-risk
person years. Age at risk assessment within our observation period
ranged from 15 to 73 years with a mean age of 37.6 (SD = 9.07),
and with mean age at death of 43.7 (SD = 9.15). More than a quar-
ter (27.4%) of our OUD cohort were found to have a comorbid
major mental illness. Majority of patients (64.2%) were admitted
into SLaM services in the subsequent 2 months after their risk
assessment was  carried out.
Associations between suicidality, accidental overdose and
unsafe injecting BRSA-A risk domains and all-cause mortality are
represented in Table 2. In the fully adjusted models with all-cause
mortality as an outcome, we found that BRSA-A assessed unsafe
injecting and likelihood of accidental overdose was associated with
increased risk of all-cause mortality (HR 1.53, 95% CI 1.10–2.11; HR
1.48, 95% CI 1.00–2.19 respectively).
We  were able to obtain data on recorded underlying cause for
68.7% of deaths in our cohort (156/227), with overdose deaths
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Table  2
Fully adjusted Cox and competing risk regression models examining associations between all-cause and cause-speciﬁc mortality and BRSA-A appraised suicidality, likelihood
of  accidental overdose and unsafe injecting in patients with opioid dependency.
Risk Cluster Fully adj.a
all-cause HR (95%
CI)
p valuea Fully adj.a SHR
for overdoseb
deaths (95% CI)
p valuea Fully adj.a SHR
for deaths other
than overdose
(95% CI)
p valuea
Suicidality
None detected Reference Reference Reference
Detected (n = 1929, 120 deaths) 1.23 (0.92–1.64) 0.154 2.89 (1.38–6.03) 0.005 0.83 (0.55–1.26) 0.378
Likelihood of Accidental Overdose
None detected Reference Reference Reference
Detected (n = 3416, 194 deaths) 1.48 (1.00–2.19) 0.049 2.82 (0.83–9.62) 0.097 1.23 (0.73–2.08) 0.43
Unsafe Injecting
None detected Reference Reference Reference
Detected (n = 2249, 161 deaths) 1.53 (1.10–2.11) 0.011 2.52 (1.11–5.70) 0.027 1.37 (0.83–2.29) 0.221
Statistically signiﬁcant (p < 0.05) hazard ratios are in bold
HR, hazard ratio; CI, conﬁdence interval; SHR, sub-distribution hazard ratio.
a Adjusted for all variables listed in Table 1.
b Accidental and intentional overdoses.
Table 3
Cox regression analyses examining associations between suicide risk domain and all-cause mortality in individuals with opioid use disorder stratiﬁed by post BRSA-A
admission to SLaM services.
Hazard Ratio (95% CI), P value
Crude HR (95% CI) p value Fully adjusteda HR (95% CI) p valuea
Not admitted (N = 1602, 90 Deaths)
No suicidality detected Reference Reference
Suicidality detected (n = 631) 2.37 (1.56–3.62) <0.001 2.03 (1.67–3.24) 0.003
Admitted (N = 2881, 137 Deaths)
No suicidality detected Reference Reference
Suicide risk detected (n = 1294) 1.27 (0.91–1.78) 0.162 0.91 (0.63–1.32) 0.636
HR, hazard ratio; CI, conﬁdence interval.
Statistically signiﬁcant (p < 0.05) hazard ratios are in bold.
a Adjusted for all variables listed in Table 1.
(both accidental and intentional) being the largest group (n = 44).
Other predominant causes of deaths within this cohort were deaths
from hepatic causes (n = 39) and infectious diseases (n = 35) (data
not shown in tables). In the fully adjusted competing risk regres-
sion models we found that BRSA-A assessed suicidality and unsafe
injecting risks were independently and signiﬁcantly associated
with increased overdose mortality (sub-distribution hazard ratio
[SHR] 2.88, 95% CI 1.38–6.03; SHR 2.52, 95% CI 1.11–5.67 respec-
tively). Likelihood of accidental overdose was not associated with
fatal overdose in these analyses.
In view of the signiﬁcant ﬁndings above, we tested for the pres-
ence of interactions between admission in the 2-month period
immediately after BRSA-A assessment and (1) suicidality, (2) acci-
dental overdose and (3) unsafe injecting domains, in models where
the outcome was all-cause mortality. An interaction between BRSA-
A suicide risk and SLaM admission was found. Additionally, in
all-cause mortality models, we tested for interactions between
the types of opioid substitute treatment (i.e., buprenorphine,
methadone, Suboxone [buprenorphine/naloxone]) and the three
BRSA-A risk domains mentioned above but none were found (data
not in tables)
After stratifying the analysis by admission to SLaM services (pre-
sented in Table 3) we found that an association between BRSA-A
suicidality and all-cause mortality was present in the group who
had not been admitted into SLaM services in the two months after
their risk assessment (HR 2.03, 95% CI 1.67–3.24), but not for the
admitted group. The Kaplan–Meier survival curve in Fig. 1 visual-
izes results for suicide risk domain stratiﬁed by admission to SLaM
service showing the reduced survival in BRSA-A patients where sui-
cidality was assessed as being present who were not admitted. Of
all those admitted, 65.9% were admitted to addiction services, with
other most common admissions being to psychological medicine
and psychosis departments (data not shown in tables).
To establish the cause of non-admission, a manual search (where
all free-text clinical notes and correspondence were reviewed) in
the electronic patient records was conducted in a random sample
of 200 patients who were not admitted to services in the 2-month
period after their risk assessment (n = 100 where suicidality was
assessed as being present in their BRSA-A; n = 100 where suici-
dality was not evident). Of those where suicidality was classiﬁed
as being present, a manual electronic patient data search revealed
that the leading causes for non-admission were loss of contact with
the patient (51%) and transfer out of services (26%). Similarly, in
the sample where suicidality was  not evident, the leading cause
for non-admissions were loss of contact with the patient (48%),
transfer out of services (22%) and incarceration (11%). No interac-
tions between BRSA-A risks of unsafe injecting and likelihood of
accidental overdose and admission to services were found.
4. Discussion
Three important ﬁndings arising from this study ought to be
noted. First, addiction-speciﬁc brief risk screen assessment may
provide useful information to identify subgroups at elevated risk of
mortality. Second, speciﬁc domains within the BRSA-A were par-
ticularly informative. Suicidality was found to be associated with
increased risk of overdose mortality; unsafe injecting practices
were associated with both all-cause and overdose mortality; and
increased likelihood of accidental overdose was associated with
all-cause mortality but not fatal overdoses. Finally, suicidality was
associated with a twofold increased all-cause mortality risk among
OUD patients who  were not admitted to mental health services
within 2 months of their risk assessment. However, we found no
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Fig. 1. Kaplan–Meier survival curve for BRSA-A suicidality domain and admissions to SLaM services (in days).
evidence that suicidality presented a similar risk in the subgroup
who were admitted into mental health services during this time
frame. These ﬁnding suggest that OUD patients with clinically evi-
dent suicidality who are not admitted to mental health services
promptly may  be particularly vulnerable
Whilst the relationship between drug injecting practices and
increased all-cause and overdose mortality in OUD is consistent
with current literature (Degenhardt et al., 2011; WHO, 2013), the
relationship between overdose, suicide and intent is not as clear.
Several studies have questioned to what extent heroin overdoses
are de facto suicide attempts. An association between heroin over-
dose and suicide was noted, for example, in a study of 77 overdose
survivors admitted to accident and emergency, with 49% report-
ing suicidal thoughts or feelings immediately prior to overdose
(Neale, 2000). In another study among a London treatment sam-
ple, 50% of those with a history of overdose had two  attempted
suicides compared to 18% of those with no history of overdose
(Vingoe et al., 2009). However, Darke and Ross, (2000) reported that
while 40% of methadone maintenance participants had attempted
suicide, only 10% had done so by means of a deliberate heroin over-
dose. Drug overdose was the most common method of attempted
suicide, but by means of non-opioid pharmaceutical preparations.
Conversely, heroin overdose among their participants overwhelm-
ingly appeared to be accidental (92%).
Our data suggest that screening positively on at least one item
within the suicidality domain, including suicide attempt and/or
ideation, carer concern or major mental illness is, independently of
accidental overdose risk factors, associated with an almost three-
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fold increase in fatal overdose. Although we do not know whether
fatal overdoses in our cohort were indeed caused by heroin, other
drugs, or a mixture of the two, it is noteworthy that in 2014 in Eng-
land and Wales, more than a half of all deaths from drug poisoning
involved an opiate drug (ONS, 2015). Second, because intent was
unknown, we  do not know which overdose deaths in our cohort
were accidental and which were suicides. However, we did ﬁnd an
association between suicidality and overdose fatalities and did not
ﬁnd associations between increased likelihood of accidental over-
dose and overdose fatalities. This could be interpreted either that
most overdose fatalities were deliberate (suicides), or that identi-
ﬁcation of patients as ‘likely to accidentally overdose’ resulted in
higher visibility to services which then resulted in improved health-
care. Increased likelihood of accidental overdose may  be addressed
within addiction services, for example, by overdose training or sup-
ply of naloxone antidote. However, suicidality may  be much more
complex and problematic to address and with the need for dual-
diagnostic/multidisciplinary care plan approaches addressing high
levels of underlying depression and other psychiatric comorbidities
(Bogdanowicz et al., 2015; Cantor et al., 2001; Darke et al., 2007).
The elevated mortality risk in patients where suicidality was
evident and who were not admitted to mental health services in
the subsequent two months, highlights the importance of admis-
sion, access to services and treatment provision. McCowan et al.
(2009) describe history of admission as being a risk factor for mor-
tality in this patient group. However, our study suggests that timing
of admission itself is a protective factor for those at risk. Further-
more, non-admission into services was largely due to loss of contact
and transfers out of service/catchment area. Drop-out from treat-
ment (and relapse) and erratic engagement in services appears to
be highly prominent in this patient group, and both are known
to increase mortality considerably (Degenhardt et al., 2011; Zanis
and Woody, 1998). Similarly, times of transition between services
involved in the care of people with opioid dependency are partic-
ularly ‘risky’, for example after release from prison (Merrall et al.,
2010). OUD patients who are assessed as being at risk of suicide and
subsequently disengage with current services may  require more
determined strategies for patient follow-ups and service transition
due to their high risk of mortality. Without better outreach for these
poorly engaging groups, current policy will broaden inequalities for
more vulnerable groups.
The results of this study need to be considered in light of cer-
tain limitations, alongside acknowledgement of strengths. SLaM is
a large provider of secondary mental healthcare in Europe, with
close to 100% monopoly provision to its geographic catchment. As
a result, we were able to draw on electronic addictions service clin-
ical records of almost ﬁve thousand OUD patients providing the
statistical power to simultaneously control for a range of potential
confounders. The inclusion criteria speciﬁed primary or secondary
OUD diagnosis. Whilst the use of NLP applications allowed us to
supplement the existing structured ﬁelds, it did not allow to us
establish whether these diagnosis were primary or secondary and
measure its impact on outcomes.
SLaM patient death-tracing is regularly updated and is based on
death certiﬁcates issued across the UK for both active and non-
active SLaM patients. This is not the case for underlying cause
of death, which derives from additional static ONS linked data.
Information on underlying cause of death was only present in
69% of cases. Additionally, as discussed, we could not differentiate
between intentional (i.e., suicide-related) and non-intentional (i.e.,
accidental) overdose deaths. Similarly, toxicology reports were not
available, and it was therefore unclear which drugs were involved
in overdose deaths.
The clinical risk assessment information used for analysis was
the ﬁrst within the observation period but may  not have been the
ﬁrst risk assessment conducted in an individual’s lifetime. Given
the mean age of our cohort as 37, there will be individuals who
have had previous treatment episodes, and subsequently previ-
ous risk assessment conducted, occurring prior to our observation
period. Similarly, we do not know if any and which circum-
stantial/treatment changes occurred in the period beyond the
subsequent two months after their risk screen and until their
death/end of observation period, which might have inﬂuenced
mortality risk in addition to clinically appraised suicide risk. How-
ever, given that a high proportion of people did not enter treatment
due to loss of contact, it seems that the combination of suicidality
and erratic engagement in services increases mortality in the longer
term.
It is important to note that our analysis investigated admissions
to mental health services across SLaM, and not addictions only. We
chose to broaden our focus because suicide risk in OUD may  not
necessarily be attended to within the addiction setting in the ﬁrst
instance, especially in cases of psychiatric comorbidity. The identi-
ﬁcation of reasons for non-admission was  extracted from a random
sample and not the entire non-admitted sub-cohort. Although the
administration of BRSA-A assessments is mandated in practice, only
84% of OUD patients had the BRSA-A scale completed. Finally, more
consideration has to be given to the brief risk assessment screen as
a measure of exposure status, which has advantages and disadvan-
tages. The BRSA-A was not formally evaluated as a measurement
in terms of constructs such as inter-rater or test-retest reliability,
or its discriminant validity. However, this is a real-world measure,
developed by clinicians and is actively used in daily practice, rep-
resenting valuable and current real-life scenarios.
Prompt identiﬁcation of those at risk is key. Our study provides
evidence that addiction-speciﬁc risk assessment may  be useful in
predicting mortality in a timely manner. The study also points out
associations between suicidality and overdose mortality in people
with opioid dependency, and highlights the importance of admis-
sion to mental health services for those where suicidality is evident.
Prompt identiﬁcation and management of those at risk using brief
risk assessment may  be useful to save time, save costs and, most
importantly, to save lives.
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